Core Viewpoint - The company has completed the fundraising project for the application development of a tumor companion diagnostic technology platform and has decided to conclude the project, utilizing the raised funds effectively [1] Group 1 - The company has fully utilized the raised funds for the project, achieving the main research and development goals [1] - The remaining raised funds amounting to 14,800 yuan will be permanently added to the company's working capital [1]

Core Points - The company has completed the fundraising project "Application Development Project Based on Tumor Companion Diagnosis Technology Platform" and will use the remaining funds of 14,800 yuan to supplement working capital [1][5] - The total amount raised from the initial public offering was 713.27 million yuan, with a net amount of 639.95 million yuan after deducting issuance costs [1][2] - The project had a planned investment of 496.65 million yuan, with an actual investment of 367.55 million yuan, resulting in a surplus of 1.48 million yuan [2][3] Fundraising Overview - The company issued 23.34 million shares at a price of 30.56 yuan per share, raising a total of 713.27 million yuan [1][2] - The funds were stored in a dedicated account and managed under a regulatory agreement with the underwriter and the bank [2] Project Details - The project aimed to develop applications based on tumor companion diagnosis technology, with a total planned investment of 496.65 million yuan [2][3] - The actual investment was 367.55 million yuan, with a remaining surplus of 1.48 million yuan [3] Approval Process - The completion of the fundraising project and the use of surplus funds do not require board approval or explicit consent from the underwriter, as per the regulations [5]